Clinical Trial Update: A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Rituxan (rituximab) with beta-glucan PGG in relapsed indolent B-cell non-Hodgkin lymphoma has completed, with results posted in January…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Indolent B-cell Non-hodgkin Lymphoma
• Indolent Non-hodgkin Lymphoma

Drugs mentioned

• B-Glucan PGG (beta-glucan PGG)
• Rituxan (rituximab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas | Phase 2 | Status: COMPLETED | Results posted: 2021-01-07